Bayer AG

Bayer AG

Health CarePharmaceuticals & Biotechnology
  • Price (EUR)98.55
  • Today's Change0.01 / 0.01%
  • Shares traded459.24k
  • 1 Year change-7.46%
  • Beta0.9854
Data delayed at least 15 minutes, as of Feb 19 2018 11:48 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Feb 17, 2018, the consensus forecast amongst 30 polled investment analysts covering Bayer AG advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Feb 06, 2006. The previous consensus forecast advised investors to hold their position in Bayer AG.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.

Share price forecast

The 27 analysts offering 12 month price targets for Bayer AG have a median target of 124.00, with a high estimate of 144.00 and a low estimate of 100.00. The median estimate represents a 25.84% increase from the last price of 98.54.


Dividend information is not available for Bayer AG.
Div growth (TTM)8.00%
More ▼

Earnings history & estimates

On Oct 26, 2017, Bayer AG reported 3rd quarter 2017 earnings of 1.47 per share. This result was in line with the consensus of the 11 analysts following the company and under-performed last year's 3rd quarter results by 15.03%.
The next earnings announcement is expected on Feb 28, 2018.
Average growth rate+9.81%
Bayer AG reported annual 2016 earnings of 7.32 per share on Feb 22, 2017.
The next earnings announcement from Bayer AG is expected the week of Feb 28, 2018.
Average growth rate+8.20%
More ▼

Revenue history & estimates

Bayer Aktiengesellschaft had 3rd quarter 2017 revenues of 8.03bn. This missed the 9.66bn consensus estimate of the 11 analysts following the company. This was 28.74% below the prior year's 3rd quarter results.
Average growth rate-6.28%
Bayer Aktiengesellschaft had revenues for the full year 2016 of 46.77bn. This was 0.96% above the prior year's results.
Average growth rate+4.20%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.